Drug Database
Back to search

Poland· PL-100433397

Givlaari

A givosiran product containing givosiranum, registered in Poland by Alnylam Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC A16AX16

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGivlaariATCA16AX16REGISTER NO.PL-100433397PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about givosiranumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Givosiran is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search givosiran products by name

Givosiran · ATC A16AX16

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Givosiranum
Manufacturer
Alnylam Netherlands B.V.
Country
Poland (PL)
ATC code
A16AX16
ATC class
Givosiran
Defined daily dose
5.8 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    08720165814046

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

105 interactions on record for givosiran.

Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check givosiran against other medicinesHow interaction checks work

Givosiran · interactions on record

105 records

  • 24 severe
  • 81 moderate

Most severe, free to view

  • EliglustatA16AX10severe
  • TemsirolimusL01EG01severe
  • EverolimusL01EG02severe
  • SirolimusL01EG04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Givosiran in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All givosiran products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Givlaari
  • Liechtenstein · Givlaari
  • Norway · Givlaari

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eefee629-c8ee-4628-9c92-439906095248
GET /v1/drugs/eefee629-c8ee-4628-9c92-439906095248?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "189 mg/ml",
  "packaging": "08720165814046 ¦ Rpz ¦ EU/1/20/1428/001 ¦ 135788\n1 fiol. 1 ml\n¦ UR/Z/4b/023/25 - 08720165814046 ¦ UR/Z/4b/122/23 - 08720165814046 ¦ UR/Z/4b/024/21 - 08720165814046 ¦ UR/Z/4b/133/22 - 08720165814046 ¦ UR/Z/4b/034/24 - 08720165814046 ¦ UR/Z/4b/161/24 - 08720165814046 ¦ UR/Z/4b/189/22 - 08720165814046 ¦ UR/Z/4b/263/25 - 08720165814046 ¦ UR/Z/4b/006/26 - 08720165814046 ¦ UR/Z/4b/063/26 - 08720165814046 ¦ UR/Z/4b/152/26 - 08720165814046",
  "substance": "Givosiranum 189 mg/ml",
  "common_name": "Givosiranum",
  "pl_product_id": "100433397",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about givosiran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console